G-CSF reduces loss of dopaminergic neurons by inhibiting TNF-α and IL-1β in mouse model of Parkinson’s disease

References

• Khan AU, Akram M, Daniyal M, et al. Awareness and current knowledge of Parkinson’s disease: a neurodegenerative disorder. Int J Neurosci. 2019;129(1):55–93.
   PubMed Web of Science ®Google Scholar
• Varadi C. Clinical features of Parkinson’s disease: the evolution of critical symptoms. Biology (Basel). 2020;9(5):1–13.
   Google Scholar
• Xu L, He D, Bai Y. Microglia-mediated inflammation and neurodegenerative disease. Mol Neurobiol. 2016;53(10):6709–6915.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Boyes BE, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38(8):1285–1291.
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Hunot S, Damier P, et al. Glial cells and inflammation in Parkinson’s disease: a role in neurodegeneration?Ann Neurol. 1998; 44(Suppl 1):S115–S120.
   Google Scholar
• Lofrumento DD, Saponaro C, Cianciulli A, et al. MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation. 2011;18(2):79–88.
   PubMed Web of Science ®Google Scholar
• Garcia-Dominguez I, Vesela K, Garcia-Revilla J, et al. Peripheral inflammation enhances microglia response and nigral dopaminergic cell death in an in vivo MPTP model of Parkinson’s disease. Front Cell Neurosci. 2018;12(398)
   Google Scholar
• Schneider A, Krüger C, Steigleder T, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest. 2005;115(8):2083–2098.
   PubMed Web of Science ®Google Scholar
• Pollari E, Savchenko E, Jaronen M, et al. Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2011;8(1):74
   PubMedGoogle Scholar
• Jiang H, Liu CX, Feng JB, et al. Granulocyte colony-stimulating factor attenuates chronic neuroinflammation in the brain of amyloid precursor protein transgenic mice: an Alzheimer’s disease mouse model. J Int Med Res. 2010;38(4):1305–1312.
   PubMed Web of Science ®Google Scholar
• Cui WY, Li MD. Nicotinic modulation of innate immune pathways via α7 nicotinic acetylcholine receptor. J Neuroimmune Pharmacol. 2010;5(4):479–488.
   PubMed Web of Science ®Google Scholar
• SchäBitz W-R, Kollmar R, Schwaninger M, et al. Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke. 2003;34(3):745–751.
   PubMed Web of Science ®Google Scholar
• Su JJ, Zhou HG, Tao YH, et al. G-CSF protects human brain vascular endothelial cells injury induced by high glucose, free fatty acids and hypoxia through MAPK and Akt signaling. PLoS One. 2015;10(4):e0120707
   PubMed Web of Science ®Google Scholar
• Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update. Arch Toxicol. 2015;89(6):867–882.
   PubMed Web of Science ®Google Scholar
• Bohush A, Niewiadomska G, Filipek A. Role of mitogen activated protein kinase signaling in Parkinson’s disease. Int J Mol Sci. 2018;19(10):1–17.
   Web of Science ®Google Scholar
• Rai SN, Singh P. Advancement in the modelling and therapeutics of Parkinson’s disease. J Chem Neuroanat. 2020;104:101752
   PubMed Web of Science ®Google Scholar
• Pain S, Gochard A, Bodard S, et al. Toxicity of MPTP on neurotransmission in three mouse models of Parkinson’s disease. Exp Toxicol Pathol. 2013;65(5):689–694.
   PubMedGoogle Scholar
• Luchtman DW, Shao D, Song C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson’s disease. Physiol Behav. 2009;98(1-2):130–138.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Salvatore MF, Maiolo SA, et al. Tyrosine hydroxylase as a sentinel for central and peripheral tissue responses in Parkinson’s progression: Evidence from clinical studies and neurotoxin models. Prog. Neurobiol. 2018.
   Web of Science ®Google Scholar
• Lee ST, Park JE, Kim DH, et al. Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington’s disease. Brain Res. 2008;1194:130–137.
   PubMed Web of Science ®Google Scholar
• Gibson CL, Bath PM, Murphy SP. G-CSF reduces infarct volume and improves functional outcome after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2005;25(4):431–439.
   PubMed Web of Science ®Google Scholar
• Menzie-Suderam JM, Mohammad-Gharibani P, Modi J, et al. Granulocyte-colony stimulating factor protects against endoplasmic reticulum stress in an experimental model of stroke. Brain Res. 2018;1682:1–23.
   PubMed Web of Science ®Google Scholar
• Urdzíková L, Jendelová P, Glogarová K, et al. Transplantation of bone marrow stem cells as well as mobilization by granulocyte-colony stimulating factor promotes recovery after spinal cord injury in rats. J Neurotrauma. 2006;23(9):1379–1391.
   PubMed Web of Science ®Google Scholar
• Cao XQ, Arai H, Ren YR, et al. Recombinant human granulocyte colony-stimulating factor protects against MPTP-induced dopaminergic cell death in mice by altering Bcl-2/Bax expression levels. J Neurochem. 2006;99(3):861–867.
   PubMed Web of Science ®Google Scholar
• Zhao LR, Navalitloha Y, Singhal S, et al. Hematopoietic growth factors pass through the blood-brain barrier in intact rats. Exp Neurol. 2007;204(2):569–573.
   PubMed Web of Science ®Google Scholar
• Vila M, Jackson-Lewis V, Vukosavic S, et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2001;98(5):2837–2842.
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39(6):889–909.
   PubMed Web of Science ®Google Scholar
• Meredith GE, Rademacher DJ. MPTP mouse models of Parkinson’s disease: an update. J Parkinsons Dis. 2011;1(1):19–33.
   PubMedGoogle Scholar
• Chamoli M, Chinta SJ, Andersen JK. An inducible MAO-B mouse model of Parkinson’s disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics. J Neural Transm (Vienna)). 2018;125(11):1651–1658.
   PubMed Web of Science ®Google Scholar
• Muñoz-Manchado AB, Villadiego J, Romo-Madero S, et al. Chronic and progressive Parkinson’s disease MPTP model in adult and aged mice. J Neurochem. 2016;136(2):373–387.
   PubMed Web of Science ®Google Scholar
• Donat CK, Scott G, Gentleman SM, et al. Microglial Activation in Traumatic Brain Injury. Front Aging Neurosci. 2017;9(208)
   PubMedGoogle Scholar
• Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005;76(2):77–98.
   PubMed Web of Science ®Google Scholar
• Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol. 2005;57(2):168–175.
   PubMed Web of Science ®Google Scholar
• Tejera D, Heneka MT. Microglia in Neurodegenerative Disorders. Methods Mol Biol. 2019;2034:57–67.
   PubMedGoogle Scholar
• Kempuraj D, Thangavel R, Natteru PA, et al. Neuroinflammation Induces Neurodegeneration. J Neurol Neurosurg Spine. 2016;1(1):1003.
   PubMedGoogle Scholar
• Karpenko MN, Vasilishina AA, Gromova EA, et al. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson’s disease . Cell Immunol. 2018;327:77–82.
   PubMed Web of Science ®Google Scholar
• Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci. 2002;22(5):1763–1771.
   PubMed Web of Science ®Google Scholar
• Mogi M, Harada M, Riederer P, et al. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165(1-2):208–210.
   PubMed Web of Science ®Google Scholar
• Mogi M, Harada M, Kondo T, et al. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci Lett. 1994;180(2):147–150.
   PubMed Web of Science ®Google Scholar
• Chen X, Hu Y, Cao Z, et al. Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: a systematic review and meta analysis. Front Immunol. 2018;9(2122)
   Google Scholar
• Hirsch EC, Breidert T, Rousselet E, et al. The role of glial reaction and inflammation in Parkinson’s disease. Ann N Y Acad Sci. 2003;991(1):214–228.
   PubMedGoogle Scholar
• Ren B, Zhang YX, Zhou HX, et al. Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson’s disease. J Neurol Sci. 2015;348(1-2):142–152.
   PubMed Web of Science ®Google Scholar
• Lull ME, Block ML. Microglial activation and chronic neurodegeneration. Neurotherapeutics. 2010;7(4):354–365.
   PubMed Web of Science ®Google Scholar
• Hashemzaei M, Shahidi MI, Moallem SA, et al. Modulation of JAK2, STAT3 and Akt1 proteins by granulocyte colony stimulating factor following carbon monoxide poisoning in male rat. Drug Chem Toxicol. 2016;39(4):375–389.
   PubMed Web of Science ®Google Scholar
• Kim SO, Sheikh HI, Ha SD, et al. G-CSF-mediated inhibition of JNK is a key mechanism for Lactobacillus rhamnosus-induced suppression of TNF production in macrophages. Cell Microbiol. 2006;8(12):1958–1971.
   PubMed Web of Science ®Google Scholar
• Huang HY, Lin SZ, Kuo JS, et al. G-CSF protects dopaminergic neurons from 6-OHDA-induced toxicity via the ERK pathway. Neurobiol Aging. 2007;28(8):1258–1269.
   PubMed Web of Science ®Google Scholar